News

Eikon Therapeutics Expands its Discovery Labs with Second Location in Hayward, California

(Hayward, Calif. March 28, 2023) Today, Eikon Therapeutics officially opened its second location in Hayward, expanding the company’s footprint to scale its research and engineering infrastructure. Eikon is a biotechnology company that is transforming the advancement of breakthrough therapeutics through the purposeful integration of engineering and science.

Ranked: The biggest healthcare VC deals of 2022

Drug discovery and development firm Eikon Therapeutics aims to better understand biochemical regulation using proprietary platforms that can examine protein interactions in living cells.

Eikon Therapeutics Announces Lease for East Coast Base of Operations in New York City

Eikon Therapeutics Announces Long-Term Lease with Alexandria Real Estate Equities, Inc. for New Corporate Headquarters in the San Francisco Bay Area

HAYWARD, Calif. – June 16, 2022 – Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the execution of a long-term lease with Alexandria Real Estate Equities, Inc. for its new corporate headquarters. Eikon’s new headquarters will consist of approximately 285,000 square feet of office and laboratory space on a new life sciences campus being developed by Alexandria in Millbrae, California.

Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors

Eikon Therapeutics Announces the Election of Kenneth C. Frazier to Its Board of Directors

HAYWARD, CALIF – March 30, 2022 – Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Kenneth C. Frazier as an independent director effective April 1, 2022. Among the world’s most admired global business leaders, Mr. Frazier is the executive chairman and former CEO of Merck (NYSE:MRK), chairman of health assurance initiatives at the venture capital firm General Catalyst, and a director of Exxon Mobil Corporation (NYSE:XOM).

Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team

HAYWARD, Calif. – January 6, 2022 – Eikon Therapeutics, Inc., a pioneer in the application of live-cell super-resolution microscopy to drug discovery, today announced that it has closed a $517.8 million Series B financing. Since its founding two years ago, Eikon Therapeutics has raised more than $668 million to advance its mission of inventing new therapies that address grievous illness.

Top Life Sciences Startups to Watch in 2022

BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.

34 healthcare and biotech startups that are set to take off in 2022, according to top investors

Eikon is now being led by one of the drug industry's most accomplished R&D leaders: Roger Perlmutter, who left the drug-making giant Merck to become CEO of Eikon in May 2021.

C&EN’s 2021 10 Start-Ups to Watch

Superresolution fluorescence microscopy shines a light on protein movement in living cells to aid drug discovery

The Endpoints 11: They've got mad money and huge ambitions. It's time to go big or go home

These days, selecting a group of private biotechs for the Endpoints 11 spotlight begins with a sprint to get ahead of IPOs and the M&A teams at Big Pharma.

Eikon Therapeutics Appoints Alfred Bowie Jr, PhD as Chief Financial Officer

HAYWARD, Calif. (BUSINESS WIRE) Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has named Alfred “Freddie” Bowie, Jr, PhD, to the newly created position of Chief Financial Officer. In this role, Dr. Bowie will have broad responsibility for finance, operational functions, and business development.

Eikon Therapeutics Closes $148 Million Series A Financing to Develop High-Throughput, Super-Resolution Microscopy for Drug Discovery

HAYWARD, Calif.--(BUSINESS WIRE)--Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. The company also announced the appointment of Roger M. Perlmutter, MD, PhD, as its new Chief Executive Officer.

Perlmutter named CEO of Eikon, a biotech with $148M to apply Nobel-winning tech to undruggable targets

Roger Perlmutter, M.D., Ph.D., has taken up the CEO post at Eikon Therapeutics. The startup disclosed the hiring of the former president of Merck Research Laboratories alongside news that it has raised a $148 million series A round to apply live-cell super-resolution microscopy to drug discovery.